Bristol Myers' Opdivo/Chemo Shows Durable Results At Four Years In Lung Cancer Patients
Portfolio Pulse from Vandana Singh
Bristol Myers Squibb released four-year follow-up data from the Phase 3 CheckMate -9LA trial, showing that patients with metastatic non-small cell lung cancer who received the combination of Opdivo and Yervoy with two cycles of chemotherapy had sustained, durable survival benefits compared to chemotherapy alone. The results will be presented at the 2023 ASCO annual meeting.
June 05, 2023 | 10:10 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Bristol Myers Squibb's Opdivo/Yervoy combination shows promising results in lung cancer patients, potentially boosting the company's position in the oncology market.
The positive results from the Phase 3 CheckMate -9LA trial demonstrate the effectiveness of Bristol Myers Squibb's Opdivo/Yervoy combination in treating metastatic non-small cell lung cancer. This could lead to increased demand for the treatment and strengthen the company's position in the oncology market, potentially driving up the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100